{"id":"NCT02091739","sponsor":"Merz Pharmaceuticals GmbH","briefTitle":"Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions","officialTitle":"Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04","primaryCompletion":"2015-08","completion":"2016-11","firstPosted":"2014-03-19","resultsPosted":"2018-02-15","lastUpdate":"2018-03-27"},"enrollment":184,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Troublesome Sialorrhea","Parkinson's Disease","Post-stroke","Traumatic Brain Injury"],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (100 Units)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"IncobotulinumtoxinA (75 Units)","otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"IncobotulinumtoxinA (Xeomin) (100 Units)","type":"EXPERIMENTAL"},{"label":"IncobotulinumtoxinA (Xeomin) (75 Units)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of chronic troublesome sialorrhea that occurs as a result of various neurological conditions in adult subjects.","primaryOutcome":{"measure":"MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4","timeFrame":"Baseline and Week 4","effectByArm":[{"arm":"MP: Placebo","deltaMin":-0.04,"sd":0.033},{"arm":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","deltaMin":-0.06,"sd":0.027},{"arm":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","deltaMin":-0.13,"sd":0.026}],"pValues":[{"comp":"OG000 vs OG002","p":"= 0.004"},{"comp":"OG000 vs OG001","p":"= 0.542"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":31,"countries":["Germany","Poland"]},"refs":{"pmids":["31794936","30918101"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":36},"commonTop":["Dry mouth","Fall","Hypertension","Nasopharyngitis","Tooth extraction"]}}